Feyerabend, M.
Pommer, S.
Mestern, S. https://orcid.org/0000-0001-5062-6712
Jimenez-Sosa, M. S.
Rachel, J.
Sunstrum, J.
Preuss, F. https://orcid.org/0009-0000-0184-3243
Khatibi, V. A.
Hinkel, R. https://orcid.org/0000-0002-2936-0400
Mietsch, M.
Vijayraghavan, S. https://orcid.org/0000-0001-7510-0055
Everling, S. https://orcid.org/0000-0001-9714-9757
Treue, S. https://orcid.org/0009-0001-8938-5810
Arnsten, A. F. T. https://orcid.org/0000-0002-3420-1308
Lewis, D. A. https://orcid.org/0000-0002-3225-6778
Tripathy, S. J. https://orcid.org/0000-0002-1007-9061
Gonzalez-Burgos, G. https://orcid.org/0000-0002-1650-8111
Inoue, W. https://orcid.org/0000-0002-2438-5123
Neef, A. https://orcid.org/0000-0003-4445-7478
Staiger, J. F. https://orcid.org/0000-0001-5694-9723
Martinez-Trujillo, J. https://orcid.org/0000-0003-3338-578X
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
Article History
Received: 27 January 2025
Accepted: 18 May 2026
First Online: 9 June 2026
Competing interests
: D.A. Lewis received investigator-initiated research support from Merck in 2025, and in 2024, he served as a paid consultant for Delix Therapeutics, LSV Capital Management, LLC, and Ono Pharma USA, Inc. The remaining authors declare no competing interests.